VEGF Inhibitor Shows Promise in Neurofibromatosis (CME/CE)

Courtesy MedPage Today Surgery  Wed, 07/08/2009 - 15:00

HOUSTON (MedPage Today) -- A majority of patients with type 2 neurofibromatosis had objective tumor responses to treatment with bevacizumab (Avastin), data from a small clinical trial showed.


 

More related items

SABCS: Delay Chemo to Aid Wound Healing (CME/CE)
SAN ANTONIO (MedPage Today) -- Therapy for metastatic breast cancer that includes bevacizumab (Avastin) should be delayed at least seven days after venous access lines are implanted to...

Avastin Stems Vision Loss in Diabetics, Cataract...
PRINCETON, N.J. (MedPage Today) -- Bevacizumab (Avastin) stemmed vision loss in diabetics and cataract surgery patients suffering from macular edema, according to new studies.

SIR: Early Wound Healing Problematic With Bevacizumab
SAN DIEGO (MedPage Today) -- Recent central line placement may require time out from bevacizumab (Avastin) treatment to avoid wound-healing complications, researchers said.

Burt's Bees Free Head to Toe Starter Kit

Lobe Wonder Ear Support Patches For Earrings,...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
health-fitness.marc8.com